On March 20, 2024, at the Annual Congress of the Société Francophone du Diabète, two presentations highlighted the progress of the INTERCEPT-T2D project (CHUL and AP-HP)
On March 20, 2024, at the Annual Congress of the Société Francophone du Diabète, two INTERCEPT-T2D presentations highlighted project progress: CHUL’s presentation described the main objectives of INTERCEPT-T2D and outlined the clinical study protocol, while AP-HP’s detailed the CORDiA cohort’s setup for patient follow-up and outlined preparations for a trial of an anti-inflammatory therapy.